Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab

Alvotech and Dr. Reddy’s Laboratories have announced a partnership to develop and commercialize a biosimilar for pembrolizumab, the active ingredient in Keytruda, which is widely used in cancer treatment. The collaboration seeks to accelerate the development process and expand global access to this critical therapy, targeting markets worldwide.

Pembrolizumab is an immune checkpoint inhibitor that has been approved for treating various types of cancer, including melanoma, lung cancer, and head and neck cancers. By focusing on creating a biosimilar version of this drug, Alvotech and Dr. Reddy’s aim to provide a more affordable alternative while maintaining efficacy standards. The agreement highlights both companies’ commitment to addressing the growing demand for accessible oncology treatments across diverse regions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Leadership Expert Links Resilience to Self-Awareness, Teamwork, and Personal Worth. FDA Advisory Committees to Replace Industry Representatives with Patients and Caregivers NAPOLI-3 Trial Highlights NALIRIFOX Dosing Adjustments and Toxicity Management for Metastatic Pancreatic Cancer Treatment Eli Lilly Partners with Camurus in $870 Million Deal to Develop Long-Acting Obesity Treatments

Author

Mark Chiang